The Behavioral Mapping of Psychomotor Slowing in Psychosis Demonstrates Heterogeneity Among Patients Suggesting Distinct Pathobiology

Niluja Nadesalingam1,*, Stéphanie Lefebvre1,*, Danai Alexaki1,2, Daniel Baumann Gama1, Florian Wüthrich1,*, Alexandra Kyrou1, Hassen Kerkeni3, Roger Kalla1, and Sebastian Walther1,*

1Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland; 2Klinik Sonnenhalde AG Psychiatrie und Psychotherapie, Basel, Switzerland; 3Department of Neurology, Inselspital University Hospital Bern, Bern, Switzerland

*To whom correspondence should be addressed; Translational Research Center, University Hospital of Psychiatry and Psychotherapy, Bolligenstrasse 111, 3000 Bern 60, Switzerland. tel +41 31 930 9755, fax +41 31 632 8950, e-mail: niluja.nadesalingam@upd.unibe.ch

Introduction

Schizophrenia is a severe and potentially disabling mental disorder with a lifetime prevalence of 1%.1 Frequent symptoms of schizophrenia include hallucinations, delusions, disorganization, negative symptoms, but also motor abnormalities. One of these motor abnormalities is Psychomotor slowing (PS). PS refers to the slowing of both mental processes and physical activities. It encompasses slowness of thoughts as well as an observable decrease in movement initiation, amount, and velocity, visible in gross motor behavior such as gait, and in fine motor behavior such as writing, but also in facial expression.2,3 Whereas the slowing of motor behaviors is readily defined, the boundaries of the term “psychomotor” remain debated. On one hand, psychomotor includes the cognitive processes (ie, the prefix psycho) responsible for movements as well as the execution of movements (ie, the root word motor).2,3 But “psychomotor” is also used to describe how motor behavior, cognition and emotion interact on the neural level.5,6 The current report focuses on psychomotor behaviors, therefore, we are considering PS as combination of action planning and execution, knowing that multiple affective, and cognitive factors may interact.

PS is prevalent across all stages of schizophrenia, independent of the current medication dosage.1,7-9 PS is not only associated with poor cognition, lower functioning, higher levels of sedentary behavior, and cardio-metabolic risks in schizophrenia, but also with poor neuropsychological and functional outcomes across serious mental illnesses.10-17 Current treatment options for schizophrenia fall short of alleviating PS,2,3 calling for novel interventions, eg, non-invasive brain stimulation.18,19 These interventions will be
informed by the pathobiology of PS. But studies on PS pathobiology require precise phenotyping and measurement, which the field is currently lacking. Particularly, the use of specific rating scales and objective instrumentation are recommended to study PS.20,21 But few studies have assessed PS outside neurocognitive tests with measures that have real-world face validity. In addition, prior studies on motor abnormalities in schizophrenia focused on syndromes that overlap with PS, such as neurological soft signs, negative symptoms, parkinsonism, or catatonia,3 while they measure broader constructs.22,23

Broad clinical rating scales often include a single item on “Motor Retardation,” which combines slowing of movements, speech, and thought. However, specificity and validity of single items have been challenged.24,25 Thus, specific expert rating scales, such as the Salpêtrière Retardation Rating Scale (SRRS) have been advocated.4,26,27 Instrumental measures of motor behavior such as actigraphy allow for continuous monitoring of physical activity in real-life.20,28 Lower activity as assessed by actigraphy was linked to more severe PS and negative symptoms in schizophrenia, while lower predictability of movement patterns was associated with positive symptom severity and disorganized behavior.25,27,29,30 Furthermore, actigraphy studies in psychosis linked sedentary behavior to illness chronicity, poor cognition, parkinsonism and catatonia.23,31–34 Gait analysis is another instrumental method to assess gross motor behavior, yet limited to the lab setting. For example, gait velocity is reduced in patients with schizophrenia compared to healthy controls (HC).35,36 Finally, fine motor behavior can be quantified with the coin rotation (CR) test, demonstrating reduced manual dexterity performance in schizophrenia vs controls.37–39 While there has been some work on PS in schizophrenia, the majority of studies limited the evaluation of PS to few measures of either gross or fine motor behavior, thus there is a lack of studies integrating multiple measures of PS.

PS can be conceptualized in the framework of the Research Domain Criteria (RDoC) initiative’s sensorimotor domain. RDoC aims at exploring these domains across multiple units of analysis, for example, genes, molecules, circuits, behavior, and self-report.40,41 This study aimed to understand the mechanisms of PS in schizophrenia within the RDoC framework. Thus, we aimed to provide extensive behavioral phenotyping of PS using 3 units of analysis: behavior (using expert ratings with SRRS), self-report, and physiology (using instrumental measures such as actigraphy, gait velocity, and CR) in a large sample of slowed patients with schizophrenia. To disentangle the behaviors specific to PS from general alterations in schizophrenia, we tested patients with schizophrenia and PS vs. patients with schizophrenia without PS vs. HC. We hypothesized that slowed patients with schizophrenia present impairments within all 3 units of analysis compared to non-slowed patients and HC, eg, slower gait, lower activity levels, and less self-reported activity. In addition, we hypothesized that within schizophrenia patients motor measures are correlating with each other; especially actigraphy activity levels should strongly correlate with expert ratings of PS. Finally, we will explore whether there are subgroups of patients with unique PS patterns.

Material and Method

Participants

We included the baseline data of the OCoPS-P study (Overcoming Psychomotor Slowing in Psychosis; ClinicalTrials.gov Identifier: NCT03921450), which is a prospective randomized clinical trial in patients with schizophrenia spectrum disorders (schizophrenia, schizoaffective, or schizophasiform disorders) according to DSM-5 (as assessed with the SCID). We analyzed the data of 71 patients with schizophrenia and PS according to the SRRS36 (SRRS, total score ≥15), 25 schizophrenia patients without PS (non-PS, SRRS score <15), and 42 HC (table 1).

All patients were recruited at the in- and out-patient departments of the University Hospital of Psychiatry and Psychotherapy, Bern, Switzerland. Six patients (3 with PS and 3 without PS) were outpatients at the time of assessment. HC were recruited from the community by using flyers and word of mouth. They were age and gender-matched with patients. All participants provided written informed consent. The study protocol adhered to the declaration of Helsinki and was approved by the local ethics committee. General exclusion criteria were active substance dependence excluding nicotine, neurological disorders, which impacted motor behavior, and traumatic brain injury. Additional exclusion criteria for HC were history of any psychiatric disorder or any first degree relative with psychosis.

Measures

General Psychopathology. We collected data on general symptom severity using the Positive And Negative Syndrome Scale (PANSS),24 parkinsonism, catatonia, and dyskinesia, using the Unified Parkinson’s Disease Rating Scale Part III (UPDRS), the Bush-Francis Catatonia Rating Scale (BFCRS) and the Abnormal Involuntary Movement Scale (AIMS) respectively.42–44 All patients were on antipsychotic medication and mean olanzapine equivalents (OLZ eq.) were calculated according to Leucht.45

Expert Ratings of Psychomotor Slowing. We assessed PS using the 15-item SRRS which ranges from 0 to 60 and combines cognitive and pure motor symptoms.36 The SRRS total score was used as the classification criterion for PS with SRRS >15 as cutoff. However, as this
report aims to provide behavioral phenotyping of PS, we extracted the items focusing exclusively on observable motor behavior in PS. The mSRRS is the sum of the pure motor items (items 1–5 and 15), with higher scores indicating more severe PS.4

Self-report of Physical Activity. We assessed the activity during the past week by using the 7-item International Physical Activity Questionnaire (IPAQ). IPAQ has been used in epidemiological studies to calculate total physical activity and energy expenditure.46 While self-reported physical activity probably is reduced in subjects with PS, the IPAQ is not assessing PS specifically.

Physiology: Instrumental Measures of Psychomotor Slowing. We assessed gross motor behavior using the triaxial-accelerometer Move4 (movisens GmbH, Karlsruhe, Germany).28 Participants wore the wrist actiwatch on their non-dominant hand for 24h. The movement counts were stored in 60s intervals. Actigraphy data were processed using Movisens Software and Excel. We used the IPAQ to calculate the total activity count during 24h. Data were missing for 1 participant.

Table 1. Demographic and Clinical Data

<table>
<thead>
<tr>
<th></th>
<th>HC</th>
<th>PS</th>
<th>Non-PS</th>
<th>Group Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>42</td>
<td>71</td>
<td>25</td>
<td>—</td>
</tr>
<tr>
<td>Age in years</td>
<td>37.0 ± 12.7</td>
<td>36.5 ± 12.5</td>
<td>34.2 ± 12.3</td>
<td>$F(2, 135) = 0.42, P = .661$</td>
</tr>
<tr>
<td>Gender</td>
<td>21M</td>
<td>36M</td>
<td>12M</td>
<td>$X^2(N = 138) = 0.05, P = .973$</td>
</tr>
<tr>
<td>Education in years</td>
<td>16.1 ± 3.2</td>
<td>13.0 ± 2.4</td>
<td>12.8 ± 1.9</td>
<td>$F(2, 135) = 21.52, P &lt; .001$</td>
</tr>
<tr>
<td>Duration of illness in years</td>
<td>—</td>
<td>10.7 ± 10.3</td>
<td>7.9 ± 9.3</td>
<td>$t(26.6) = -0.5, P = .605$</td>
</tr>
<tr>
<td>Nr. of episodes</td>
<td>—</td>
<td>5.1 ± 4.6</td>
<td>6.4 ± 12.0</td>
<td>$t(94) = 3.9, P &lt; .001$</td>
</tr>
<tr>
<td>PANSS Total</td>
<td>—</td>
<td>82.5 ± 19.1</td>
<td>66.2 ± 14.2</td>
<td>$t(94) = 0.3, P = .785$</td>
</tr>
<tr>
<td>PANSS Positive</td>
<td>—</td>
<td>16.5 ± 5.8</td>
<td>16.9 ± 5.1</td>
<td>$t(94) = 6.0, P &lt; .001$</td>
</tr>
<tr>
<td>PANSS Negative</td>
<td>—</td>
<td>24.5 ± 6.6</td>
<td>15.8 ± 4.8</td>
<td>$t(94) = 0.9, P = .383$</td>
</tr>
<tr>
<td>PANSS Depression G6</td>
<td>—</td>
<td>2.6 ± 1.4</td>
<td>2.3 ± 1.3</td>
<td>$t(94) = 0.9, P = .386$</td>
</tr>
<tr>
<td>Medication OLZ eq. in mg</td>
<td>—</td>
<td>16.8 ± 11.0</td>
<td>14.6 ± 10.3</td>
<td>$t(84.9) = 6.8, P &lt; .001$</td>
</tr>
<tr>
<td>UPDRS</td>
<td>—</td>
<td>21.9 ± 12.6</td>
<td>8.8 ± 6.1</td>
<td>$t(93.98) = 7.6, P &lt; .001$</td>
</tr>
<tr>
<td>BFCRS</td>
<td>—</td>
<td>6.2 ± 4.7</td>
<td>1.3 ± 1.6</td>
<td>$t(74.6) = 3.0, P = .004$</td>
</tr>
<tr>
<td>AIMS</td>
<td>—</td>
<td>1.0 ± 2.5</td>
<td>0.1 ± 0.3</td>
<td>—</td>
</tr>
</tbody>
</table>

Note: Displayed are mean ± sd of demographic and clinical variables for each of our 3 groups. Sd, Standard deviation; PANSS, Positive And Negative Syndrome Scale; OLZ eq., Olanzapine-equivalent (mg/day); UPDRS, Unified Parkinson Disease Rating Scale Part III; BFCRS, Bush-Francis Catatonia Rating Scale; AIMS, Abnormal Involuntary Movement Scale; M, male; HC, Healthy Controls; PS, Patients with Psychomotor Slowing; non-PS, Patients without Psychomotor Slowing.

Finally, fine motor skills were assessed with the CR task. Participants had to rotate a Swiss 50-Rappen coin, comparable to the size of a US dime with a diameter of 18.2mm, between thumb, index, and middle finger as fast as possible. They performed 3 trials of 10s with each hand. Video recordings of CR performance were scored blind to participant status. The first trial was a practice trial. The score of trials 2 and 3 was averaged. We calculated the CR score for each trial using the following validated formula: CR score = half turns − [(coin drops × 0.10) × half turns].

Data Analysis

First, we compared the 3 groups PS, non-PS, and HC on demographic and clinical parameters with IBM SPSS Statistics (v28.0.0.0). Next, we used ANCOVAs to compare mSRRS, IPAQ, activity count, gait velocity, and CR between the three groups by controlling for age followed by post hoc tests between patients and controls with Sidak correction for multiple comparisons. As motor measures in patients are potentially associated with antipsychotic medication and illness severity (supplementary table S1A–C), we additionally run ANCOVAs to compare each measure between PS and non-PS patients using age, negative symptoms (assessed by PANSS negative) and medication (OLZ) as covariates. Furthermore, we conducted nonparametric partial correlations (Spearman) with age, medication and negative symptoms as covariates to explore potential associations of the different measures of PS in schizophrenia patients. For each measure, we controlled for multiple comparisons using the false discovery rate (FDR). Additionally, we ran binary logistic regressions to test the classification into PS and non-PS patients by using either activity level as a predictor or...
all instrumental motor measures (activity level, gait velocity, and both CR-Task performances) as predictors. Furthermore, we ran a k-means cluster analysis on the activity levels and compared the resulting groups (high vs low activity) on motor measures and psychopathology. Finally, to explore subgroups among PS patients, we performed a cluster analysis within the PS group on all instrumental measures and compared the resulting clusters regarding psychopathology, demographics, illness duration, medication, expert ratings of motor abnormalities, self-report, and instrumental assessments of PS. The missing values were replaced with the mean value of each measure.

Results

Demographic and Clinical Information

Patients with schizophrenia and PS (n = 71), without psychomotor slowing (non-PS, n = 25), and HC (n = 42) did not differ in age or gender. PS patients had more severe symptoms compared to non-PS patients, including negative symptoms, dyskinesia, parkinsonism, and catatonia. However, patient groups did not differ in current medication dosage, duration of illness, or PANSS depression ratings (table 1).

Group Comparison of Motor Assessments

Expert Ratings of Behavior. ANCOVAs indicated that PS had higher mSRRS scores than HC and non-PS (figure 1, table 2), reflecting the categorization of patients using the total SRRS cutoff.

Self-report. HC reported more overall activity than either patient group. PS and non-PS did not differ in self-reported activity (figure 1, table 2).

Physiology: Instrumental Measures. ANCOVAs indicated lower activity levels and slower gait in PS compared to HC, while no difference emerged between HC and non-PS regarding activity levels. PS demonstrated lower activity levels than non-PS, but no difference in gait velocity when controlling for medication and PANSS negative (figure 1, table 2).

Finally, HC presented superior fine motor performance than PS patients for both hands. No difference between PS and non-PS’s in CR performance was noted on either hand (figure 1, table 2).

Correlations Analyses in Schizophrenia Patients

The activity level measured with actigraphy correlated negatively with mSRRS (rho = −0.51, P_{dr,corr} < .001), while activity levels correlated positively with all the other measures (all rho ≥ 0.22, P_{dr,corr} ≤ .032). Self-paced gait velocity also correlated with the performance on the CR task with the dominant hand (rho = 0.32, P_{dr,corr} = .01) and inversely correlated with mSRRS (rho = −0.23, P_{dr,corr} = .065) at trend level. As expected, the performance of both hands on the CR task is highly correlated (rho = 0.74, P_{dr,corr} < .001). The IPAQ was exclusively associated with actigraphy. Overall the strongest association was detected between activity levels (gold standard of instrumental PS assessment) and the mSRRS (expert rating of PS) (See figure 2 and supplementary table S3).

Logistic regression analysis indicated that actigraphy levels had 72.1% accuracy in classifying patients with PS and non-PS compared to the expert rating (Wald Chi² = 11.1, df = 1, P < .001). Accuracy is 72.3% when AL is combined with gait and CR for both hands, however, only AL contributes significantly to the model (Wald Chi² = 8.7, df = 1 P = .003). Finally, we ran a cluster analysis on AL in all patients, which found 2 clusters (low AL n = 66, high AL n = 20). Low AL had higher ratings on PS, parkinsonism, negative symptoms, catatonia, and lower CR. But clusters did not differ in OLZ, positive symptoms, gait velocity, IPAQ, or dyskinesia (supplementary table S2).

Cluster Analysis Within PS

We performed k-means clustering to explore subgroups in PS. A 2 cluster solution was the most plausible from the data. One cluster (n = 42) included subjects with pronounced impairments in manual dexterity, lower activity, and slower gait, while the other cluster (n = 29) included subjects with less impairments in all instrumental measures (supplementary figure S1). table 3 demonstrates the clinical differences between the clusters with Cluster 1 having more psychotic symptoms, higher ratings of slowing, and more parkinsonism, whereas clusters were comparable on age, gender, medication, education, catatonia severity, and self-reported activity. The rigid cluster had specifically increased ratings of rigidity and bradykinesia in UPDRS single items (supplementary table S4).

Discussion

This study aimed at exploring psychomotor slowing (PS) in psychosis from an RDoC perspective leveraging 3 units of analysis and testing PS against general impairments in schizophrenia spectrum disorders. Patients with PS differed from healthy subjects in expert ratings, self-report, and multiple instrumental measures. Patients with PS also scored higher in expert ratings and had lower instrumental activity levels compared to psychosis patients without PS. In patients, instrumental measures were strongly correlated to expert ratings of PS. Particularly, classification based on actigraphy provided similar results as classification by expert ratings. Finally, within PS patients we found 2 subgroups of severity, 1 of which...
Behavioral Mapping of Psychomotor Slowing

is characterized by massively impaired manual dexterity and parkinsonism.

Multimodal Assessment of Psychomotor Slowing

We classified the patients with schizophrenia into PS (total SRRS ≥15) and non- (total SRRS <15) groups. This distinction is also reflected in the pure motor items as patients with PS had much higher mSRRS scores than patients without PS and HC. This focus on observable motor behavior is important. While SRRS total scores share 76% of the variance of mSRRS in patients, the group difference between patients with and without PS could also stem from the non-motor items of the SRRS. Thus, those identified as slow with the broad evaluation of PS (SRRS), are specifically slower in the mSRRS. However, the non-PS patients also had higher mSRRS scores than HC, indicating mild motor slowing, which confirms the frequent presence of motor abnormalities in schizophrenia in general.\(^{16,21,51,52}\)

Both patients with and without PS report similar amounts of physical activity. This level of self-reported

![Fig. 1.](https://academic.oup.com/schizophreniabulletin/advance-article/doi/10.1093/schbul/sbac170/6839989)
Deteriorating courses in schizophrenia spectrum disorders. However, no prior study compared activity levels between psychosis patients with PS and patients without PS. The current report suggests that activity levels measured by actigraphy might be a good marker to identify PS. In fact, accuracy was good compared to expert ratings and clustering according to activity levels provided similar results as the SRRS-based classification. Actigraphy requires instruments, but rater trainings and time for ratings can be saved. In line with previous studies, gait was slower in schizophrenia than in HC.

Similarly, the assessment of fine motor behavior with CR-Task, revealed that slowed patients had a deficit in manual dexterity in both hands compared to HC. But CR-performance was not different between the PS and non-PS. CR performance was similar to previous studies in schizophrenia.

The motor performance in fine and gross motor measures appears to follow a continuum with the HC on one end and the patients with PS on the other end, the patients without slowing showing an intermediate position. Still, CR and CR lacked a group difference when controlling for OLZ and negative symptoms, suggesting a general deficit in schizophrenia. In contrast, post hoc comparisons might have approached significance if the sample size was increased, as variance and means suggest. The RDoC motor domain calls for a dimensional assessment of motor abnormalities. Here, we demonstrate specific changes in psychosis patients with PS. However, the instrumental measures and self-report could be readily applied for dimensional assessments across various disorders.

We observed much variance in the PS group, calling for exploratory cluster analysis that identified two subgroups of severity in PS based on all instrumental measures. This
Table 3. Demographic and Clinical Data of the Clusters

<table>
<thead>
<tr>
<th></th>
<th>Highly Rigid and Slowed Patients</th>
<th>Less Rigid and Slowed Patients</th>
<th>Comparison</th>
<th>FDR-corr. P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>42</td>
<td>29</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Age in years</td>
<td>37.3 ± 14.4</td>
<td>34.6 ± 11.0</td>
<td>F(1, 69) = 0.8, P = .388</td>
<td>.466</td>
</tr>
<tr>
<td>Gender</td>
<td>21M</td>
<td>15M</td>
<td>X² (1, N = 71) = 0.02, P = .886</td>
<td>.997</td>
</tr>
<tr>
<td>Education in years</td>
<td>13.0 ± 2.4</td>
<td>13.0 ± 2.4</td>
<td>F(1, 69) = .001, P = .977</td>
<td>.977</td>
</tr>
<tr>
<td>Duration of illness in years</td>
<td>12.6 ± 11.4</td>
<td>8.0 ± 7.9</td>
<td>F(1, 69) = 3.5, P = .066</td>
<td>.108</td>
</tr>
<tr>
<td>Nr. of episodes</td>
<td>6.2 ± 5.4</td>
<td>3.5 ± 2.6</td>
<td>F(1, 69) = 6.2, P = .015</td>
<td>.303*</td>
</tr>
<tr>
<td>SRRS total</td>
<td>26.3 ± 6.7</td>
<td>22.0 ± 5.0</td>
<td>F(1, 69) = 8.7, P = .004</td>
<td>.013*</td>
</tr>
<tr>
<td>PANSS Total</td>
<td>87.2 ± 21.6</td>
<td>75.7 ± 12.2</td>
<td>F(1, 69) = 6.7, P = .012</td>
<td>.026*</td>
</tr>
<tr>
<td>PANSS Positive</td>
<td>17.6 ± 6.6</td>
<td>15.0 ± 4.1</td>
<td>F(1, 69) = 3.5, P = .066</td>
<td>.100</td>
</tr>
<tr>
<td>PANSS Negative</td>
<td>26.0 ± 7.2</td>
<td>22.2 ± 4.9</td>
<td>F(1, 69) = 6.2, P = .015</td>
<td>.027*</td>
</tr>
<tr>
<td>Medication OLZ eq. in mg</td>
<td>17.7 ± 11.7</td>
<td>15.3 ± 9.7</td>
<td>F(1, 69) = 0.8, P = .374</td>
<td>.481</td>
</tr>
<tr>
<td>UPDRS</td>
<td>25.4 ± 12.1</td>
<td>16.9 ± 11.7</td>
<td>F(1, 69) = 8.7, P = .004</td>
<td>.015*</td>
</tr>
<tr>
<td>BFCSR</td>
<td>5.9 ± 4.9</td>
<td>5.2 ± 4.3</td>
<td>F(1, 69) = 2.2, P = .146</td>
<td>.203</td>
</tr>
<tr>
<td>mSRRS</td>
<td>11.5 ± 3.1</td>
<td>9.6 ± 2.9</td>
<td>F(1, 69) = 6.8, P = .011</td>
<td>.029*</td>
</tr>
<tr>
<td>IPAQ</td>
<td>1400.7 ± 2376.3</td>
<td>1382.0 ± 2324.5</td>
<td>F(1, 69) = 0.001, P = .974</td>
<td>&gt;.9</td>
</tr>
<tr>
<td>Actigraphy</td>
<td>11313.6 ± 3584.4</td>
<td>15525.2 ± 5076.9</td>
<td>F(1, 69) = 17.0, P &lt; .001</td>
<td>&lt;.001***</td>
</tr>
<tr>
<td>Gait velocity</td>
<td>94.6 ± 20.1</td>
<td>113.6 ± 19.9</td>
<td>F(1, 69) = 15.5, P &lt; .001</td>
<td>&lt;.001***</td>
</tr>
<tr>
<td>CR dominant hand</td>
<td>8.6 ± 2.4</td>
<td>14.5 ± 1.8</td>
<td>F(1, 69) = 125.9, P &lt; .001</td>
<td>&lt;.001***</td>
</tr>
<tr>
<td>CR non-dominant hand</td>
<td>7.9 ± 2.4</td>
<td>12.2 ± 2.1</td>
<td>F(1, 69) = 62.1, P &lt; .001</td>
<td>&lt;.001***</td>
</tr>
</tbody>
</table>

Note: Displayed are mean ± sd of demographic and clinical variables for each cluster within the PS group. Sd, Standard deviation; SRRS, Salpétrière Retardation Rating Scale; PANSS, Positive And Negative Syndrome Scale; OLZ eq., Olanzapine-equivalent (mg/day); UPDRS, Unified Parkinson Disease Rating Scale Part III; BFCSR, Bush-Francis Catatonia Rating Scale; mSRRS, motor score of SRRS; IPAQ, International Physical Activity Questionnaire; CR, Coin rotation task; M, male.

distinction might result from different neural substrates. While motor abnormalities and especially PS seems to be associated with alteration of the entire motor circuitry,2,5,25,29,60 the patients with less motor impairments could present alterations only in the cortical motor network (primary motor and premotor areas) leading to abnormalities in movement execution, whereas the patients with severer impairment could present additional alterations in the cortico-subcortical circuits with the basal ganglia leading to abnormalities in both movement control and movement execution.3,6,11 Particularly, one PS cluster had higher ratings of rigidity items in the UPDRS. The severity of parkinsonism has been associated to alterations in cortical and subcortical structures in schizophrenia.5,55,66 Further neuroimaging studies will need to test whether PS clusters have distinct pathobiology. Eventually, specific noninvasive brain stimulation protocols might be needed for the 2 types of PS: one addressing cortical motor dysfunction, the other targeting the entire motor circuitry.18,19 First evidence suggests an amelioration of PS by inhibitory 1 Hz stimulation of the supplementary motor area (SMA).19

**Correlation Within the Schizophrenia Patients**

The actigraphically assessed activity level correlates with all the other measures, such as gait velocity, IPAQ, and manual dexterity, which is particularly true for expert ratings. Likewise, previous studies reported an association between activity levels and PS,27 or catatonia and parkinsonism.23,33,38 Furthermore, all motor measures assessing PS (except IPAQ) correlated with severity of catatonia and parkinsonism, which is in contrast to a prior report in which neither catatonia nor parkinsonism correlated with a single item measure of PS.67 However, in line with other reports, PS was strongly associated with negative symptom severity.4,23,67-69 Together, these results suggest that actigraphy could be considered as gold standard to evaluate PS as it is correlating with different domains of psychopathology.20,21,40 One could argue that if expert ratings and actigraphy are giving the same clinical information, then actigraphy that requires time and equipment might not be a good option in clinical settings. However, time to train clinicians using the scales and to perform assessments, is also costly. Moreover, actigraphy collects data continuously also beyond the clinical interview in the patients’ environment and therefore might be more informative than a few minutes interview with a clinician who relies on observation only. It may also help patients who struggle to come to regular visits or to provide sufficient information during the interview. From the logistic regression, we learned that actigraphy has 72% accuracy compared to the SRRS-based classification, suggesting that 30% of the classification can either not be explained by the behavioral measurement or that the expert rating scale did not classify correctly the patients; which would call for actigraphy.
Clinical Implications

Given the poor outcomes associated with PS and the lack of sufficient treatment options, the field should focus on developing and testing novel treatment approaches. To design neuroimaging studies exploring the pathobiology of PS, specific behavioral markers are required. Neuroimaging studies indicated that altered structural and functional connectivity within the motor network was linked to motor abnormalities assessed with wrist actigraphy.\(^5^9\)\(^7^0\) Especially the functional connectivity to the SMA as well as the activity of SMA is altered in schizophrenia patients with PS.\(^3^,^5^9\)\(^7^1\)\(^7^2\) These findings suggest that the SMA might be an ideal entry node to the motor system that can be modulated by noninvasive brain stimulation such as repetitive transcranial magnetic stimulation (rTMS).\(^1^8\) In fact, inhibitory rTMS over the SMA ameliorated PS in schizophrenia and depression.\(^1^9\)

Further trials are on their way and maybe rTMS could become a novel treatment option for PS.

Limitations

The strength of the current report is multiple measures in a large group of schizophrenia patients with PS to explore psychomotor slowing in psychosis from an RDoC perspective with 3 units of analysis. Furthermore, this study tested the specificity of PS contrasting behaviors to patients without PS. However, there are also some limitations. First, the limited sample size of the non-slowed group has hampered the detection of smaller differences between patient groups. Furthermore, this is a cross-sectional analysis and future studies should test the longitudinal course of activity levels in slowed and non-slowed patients. In addition, current and past medication may impact PS measures. While we carefully controlled our analyses for age, current antipsychotic dosage, and negative symptoms, we could not control for total antipsychotic exposure. By trying to provide extensive phenotyping within the RDoC framework, we wanted to include self-report of PS, however, there is no questionnaire assessing self-reported PS, accordingly, we included a less specific self-report measure of physical activity, which taps into movement initiation, general motor activity, or sedentary behavior. Future research might benefit from the development of dedicated self-report instruments.\(^5^5\) Furthermore, in the current study, we focused on behavioral phenotyping of PS, and did not design the study to assess cognitive slowing. This important feature of PS should be included in future trials using cognitive assessments. In addition, PS observed in our sample might be associated with depression. The lack of a specific depression rating scale prevents us from fully exploring this question. However, the DSM-5 depression rating, as well as the PANSS G6 item, offer convergent information on depression. Using these two measures, we detected no effect of depression severity on

the observable characteristics of PS (supplementary table 1, table S1a, and S5). Finally, our study might have selection bias, as we analyzed baseline data of a randomized controlled trial. Patients with PS had all agreed to participate in a 3-week trial with multiple assessments, limiting the generalizability of the findings.

Conclusion

PS manifests in slower gait, lower activity, and slower finger movements compared to HC. However, only actigraphy and observer ratings enable the identification of PS from non-PS patients. Actigraphy may become the standard assessment of PS in neuroimaging studies and clinical trials.

Supplementary Material

Supplementary material is available at https://academic.oup.com/schizophreniabulletin/.

Funding

This work was supported by the Swiss National Science Foundation (#182469 to SW). The funding source had no further role in study design; in the collection, analysis, and interpretation of data; in writing of the report; and in the decision to submit the paper for publication.

Acknowledgments

We would like to thank all the participants of the study.

Disclosure Statement

SW has received honoraria from Lundbeck, Mepha, and Neurolite. NN, SL, DA, DB, FW, AK, HK, and RK reported no biomedical financial interests or potential conflicts of interest.

References


